These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 7494275)

  • 41. Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins.
    Taylor J; Weinberg R; Tartaglia J; Richardson C; Alkhatib G; Briedis D; Appel M; Norton E; Paoletti E
    Virology; 1992 Mar; 187(1):321-8. PubMed ID: 1736535
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Crossreactivity of mimotopes and peptide homologues of a sequential epitope with a monoclonal antibody does not predict crossreactive immunogenicity.
    El Kasmi KC; Deroo S; Theisen DM; Brons NH; Muller CP
    Vaccine; 1999 Sep; 18(3-4):284-90. PubMed ID: 10506653
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intramolecular immunodominance and intermolecular selection of H2d-restricted peptides define the same immunodominant region of the measles virus fusion protein.
    Muller CP; Bünder R; Mayser H; Ammon S; Weinmann M; Brons NH; Schneider F; Jung G; Wiesmüller KH
    Mol Immunol; 1995 Jan; 32(1):37-47. PubMed ID: 7870057
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Priming of measles virus-specific CTL responses after immunization with a CTL epitope linked to a fusogenic peptide.
    Partidos CD; Vohra P; Steward MW
    Virology; 1996 Jan; 215(1):107-10. PubMed ID: 8553582
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Humoral immunity to canine distemper after immunization of dogs with inactivated and live measles virus.
    Norrby E; Appel MJ
    Arch Virol; 1980; 66(3):169-77. PubMed ID: 7447704
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The immunologic concept of heterotypic resistance.
    Prydie J
    J Am Vet Med Assoc; 1970 Jun; 156(12):1747-50. PubMed ID: 5422524
    [No Abstract]   [Full Text] [Related]  

  • 47. Contribution of measles virus fusion protein in protective immunity: anti-F monoclonal antibodies neutralize virus infectivity and protect mice against challenge.
    Malvoisin E; Wild F
    J Virol; 1990 Oct; 64(10):5160-2. PubMed ID: 2398539
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of antibody response to the measles virus using synthetic peptides of the fusion protein. Evidence of non-random pairing of T and B cell epitopes.
    Muller CP; Handtmann D; Brons NH; Weinmann M; Wiesmüller KH; Spahn G; Wiesneth M; Schneider F; Jung G
    Virus Res; 1993 Dec; 30(3):271-80. PubMed ID: 8109160
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Measles virus antigens induce both type-specific and canine distemper virus cross-reactive cytotoxic T lymphocytes in mice: localization of a common Ld-restricted nucleoprotein epitope.
    Beauverger P; Buckland R; Wild TF
    J Gen Virol; 1993 Nov; 74 ( Pt 11)():2357-63. PubMed ID: 7504072
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protective immunity provided by HLA-A2 epitopes for fusion and hemagglutinin proteins of measles virus.
    Oh S; Stegman B; Pendleton CD; Ota MO; Pan CH; Griffin DE; Burke DS; Berzofsky JA
    Virology; 2006 Sep; 352(2):390-9. PubMed ID: 16781760
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prediction and identification of a T cell epitope in the fusion protein of measles virus immunodominant in mice and humans.
    Partidos CD; Steward MW
    J Gen Virol; 1990 Sep; 71 ( Pt 9)():2099-105. PubMed ID: 2212993
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins.
    Song MK; Vindurampulle CJ; Capozzo AV; Ulmer J; Polo JM; Pasetti MF; Barry EM; Levine MM
    J Virol; 2005 Aug; 79(15):9854-61. PubMed ID: 16014946
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction.
    Lairmore MD; DiGeorge AM; Conrad SF; Trevino AV; Lal RB; Kaumaya PT
    J Virol; 1995 Oct; 69(10):6077-89. PubMed ID: 7545241
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Humoral immune responses to a protective peptide-conjugate against measles after different prime-boost regimens.
    Pütz MM; Ammerlaan W; Schneider F; Jung G; Muller CP
    Vaccine; 2004 Oct; 22(31-32):4173-82. PubMed ID: 15474707
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epitope-specific antibody response to Mel-CAM induced by mimotope immunization.
    Hafner C; Wagner S; Jasinska J; Allwardt D; Scheiner O; Wolff K; Pehamberger H; Wiedermann U; Breiteneder H
    J Invest Dermatol; 2005 Jan; 124(1):125-31. PubMed ID: 15654965
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Measles vaccine in dogs: efficacy against aerosol challenge with virulent canine distemper virus.
    Strating A
    J Am Vet Med Assoc; 1975 Jul; 167(1):59-62. PubMed ID: 1150494
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neutralizing human Fab fragments against measles virus recovered by phage display.
    de Carvalho Nicacio C; Williamson RA; Parren PW; Lundkvist A; Burton DR; Björling E
    J Virol; 2002 Jan; 76(1):251-8. PubMed ID: 11739690
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cross-reactive and group-specific immune responses to a neutralizing epitope of the human respiratory syncytial virus fusion protein.
    Corvaisier C; Bourgeois C; Pothier P
    Arch Virol; 1997; 142(6):1073-86. PubMed ID: 9228999
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effects of a flanking sequence on the immune response to a B and a T cell epitope from the fusion protein of measles virus.
    Partidos CD; Steward MW
    J Gen Virol; 1992 Aug; 73 ( Pt 8)():1987-94. PubMed ID: 1379626
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of the neutralizing antibody response to the measles virus using synthetic peptides of the haemagglutinin protein.
    Muller CP; Schroeder T; Tu R; Brons NH; Jung G; Schneider F; Wiesmüller KH
    Scand J Immunol; 1993 Nov; 38(5):463-71. PubMed ID: 7694357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.